SCHEMBL1499133

SCHEMBL1499133

N#CCC(CN1CCN(C(=O)c2cc(F)cc(Cl)c2)CC1)n1cc(-c2ncnc3[nH]ccc23)cn1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TYRO3 Q06418 2/20 0.71
AXL P30530 2/20 0.69
MERTK Q12866 2/20 0.69
JAK2 O60674 17/20 0.56
JAK1 P23458 10/20 0.56
TYK2 P29597 2/20 0.48
JAK3 P52333 2/20 0.48
BMPR1B O00238 1/20 0.48
PLK4 O00444 1/20 0.48
STK25 O00506 1/20 0.48
CIT O14578 1/20 0.48
RIOK3 O14730 1/20 0.48
IKBKB O14920 1/20 0.48
CASK O14936 1/20 0.48
GAK O14976 1/20 0.48
DCLK1 O15075 1/20 0.48
EPHB6 O15197 1/20 0.48
DAPK3 O43293 1/20 0.48
MAP3K7 O43318 1/20 0.48
ROCK2 O75116 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL2086602 0.96 TYRO3 (0.67) TYRO3AXLMERTKJAK2JAK1
SCHEMBL1498960 0.95 TYRO3 (0.76) TYRO3AXLMERTKJAK2JAK1
SCHEMBL2088067 0.90 TYRO3 (0.75) TYRO3AXLMERTKJAK2JAK1
SCHEMBL1499421 0.90 TYRO3 (0.66) TYRO3AXLMERTKJAK2JAK1
SCHEMBL2085410 0.90 TYRO3 (0.75) TYRO3AXLMERTKJAK2JAK1
SCHEMBL1499425 0.89 TYRO3 (0.76) TYRO3AXLMERTKJAK2JAK1
SCHEMBL2085187 0.89 TYRO3 (0.77) TYRO3AXLMERTKJAK2JAK1
SCHEMBL1498988 0.88 TYRO3 (0.74) TYRO3AXLMERTKJAK2JAK1
SCHEMBL12832294 0.88 TYRO3 (0.66) TYRO3AXLMERTKJAK2JAK1
SCHEMBL2084512 0.88 TYRO3 (0.78) TYRO3AXLMERTKJAK2JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9249145-B2 Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors INCYTE HOLDINGS CORPORATION (US) 2016-02-02 US claimed
WO-2011028685-A1 HETEROCYCLIC DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-D]PYRIMIDINES AS JANUS KINASE INHIBITORS INCYTE CORPORATION (US) 2011-03-10 WO claimed
US-20110059951-A1 HETEROCYCLIC DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS INCYTE CORPORATION 2011-03-10 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110059951-A1 HETEROCYCLIC DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS JAK3, JAK1, JAK2 TYRO3 107/4885AXL 296/4885MERTK 515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.